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Summary: We have measured the bile acids in human serum as methyl ester-trimethylsilyl ethers by gas chromato-
graphy-mass spectrometry (GC-MS) using an electron ionization procedure. The overall method was validated and
the detection limit (0.4 μιηοΐ/ΐ), linearity (2—30 μιηοΐ/ΐ), intra-day and inter-day precision, accuracy and recovery
(96.2% for «or-23-deoxycholic acid as internal standard) were measured. Serum C24-bile acids profiles from 43
cholestatic patients were measured by GC-MS and by HPLC. The results obtained with the two methods were well
correlated and the criteria for selecting either HPLC or GC-MS identified. The serum C24- and C2?-bile acids and
Ci9 dicarboxylic bile acid profiles for patients with generalized peroxisomal deficiencies, like Zellweger syndrome
(n = 5), neonatal adrenoleukodystrophy (n = 1), infantile Refsum disease (n = 2) and from a single peroxisomal
deficiency (n = 1) were also measured by GC-MS.
Introduction
Primary C24-bile acids like cholic acid and chenodeoxy-
cholic acid are end products of the oxidative degradation
of cholesterol in the liver. This catabolism involves both
the sterol nucleus, with the synthesis of C2?-bile acids
intermediates like trihydroxycholestanoic acid and dihy-
droxycholestanoic acid, and the shortening of their side
chain 8 to 5 carbons by -oxidation. This last step is
located in peroxisomes (1). Glyco- and tauro-conjugated
cholic acid and chenodeoxycholic acid are then secreted
into the bile and released into the intestine, where bacte-
rial 7a-dehydroxylation of cholic acid and chenodeoxy-
cholic acid occurs to produce secondary bile acids like
deoxycholic acid and lithocholic acid and epimerization
of chenodeoxycholic acid to form ursodeoxycholic acid
(2). Biochemical abnormalities occuring during chole-
stasis or peroxisomal enzymatic defects require the sep-
aration, identification and a quantitative measurement of
the serum bile acids profile. Gas chromatography (GC)
(3) and HPLC (4) methods are the mainstays for serum
bile acids profile analysis. The high boiling points of
conjugated bile acids make deconjugation and derivati-
zation necessary for GC analysis. Conjugated bile acids
have been assayed directly by HPLC, but UV detection
is limited by the poor absorptivity of conjugated and
unconjugated bile acids (5). Sensitivity has been im-
proved using pre- or post-column derivatization and
more sensitive fluorimetric or electrochemical detectors
(6). GC and HPLC require efficient internal standards
and reference bile acids were not always available. Mass
spectrometry (MS), equipped with GC-MS (7) or
HPLC-MS (8) seems thus to be the efficient tool for
identification of bile acids during physiopathological sit-
uations. Fast atom bombardment-mass spectrometry
(FAB MS) (9), fast atom bombardment tandem mass
spectrometry (FAB MS/MS) (10), HPLC/FAB MS (11)
and negative ion chemical ionization-mass spectrometry
(NICI/MS) (12) have been described for the rapid
screening of bile acids particular to enzyme defects of
biosynthesis.The present study describes a validated
GC-MS method. We have correlated serum C24-bile
acids profiles from cholestatic patients using both the
GC-MS and HPLC methods. Bile acids profiles of pa-
tients with generalized or single peroxisomal disorders
have been investigated.
Materials and Methods
Materials
Reagents used were analytical grade and the water was ultra-pure
(resistance 18.2 ΜΩ/cm). The bile acids already mentioned, nor-
23-deoxycholic acid and 5a-cholestane were purchased from Stera-
loids, Inc., (Wilton, N. H., USA). Cholylglycine hydrolase (EC
3.5.1.24), (ref C 4018), was purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Bond Elut® Cig was purchased from Ana-
lytical International (Harbor City, CA, USA) and Lipidex 1000®
from Packard Instrument (Groningen, Netherlands). Methanolic-
hydrochloric acid was purchased from Supelco (Bellefonte, USA)
and Tri-Sil® reagent (ref 49001) from Pierce (Rockford, IL, USA).
Sample preparation
Glyco- and tauro-conjugated bile acids were removed from their
binding proteins and extracted for HPLC (13). Glyco- and tauro-
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conjugated bile acids were deconjugated, removed from their bind-
ing proteins, extracted and derivatized for GC-MS. The bile acids
of 0.3 ml serum were deconjugated with cholylglycine hydrolase
(60 U) in 0.2 mol/1 sodium acetate buffer pH 5.6 (2 ml) (20 hours,
37 °C) (14). Bile acids were released from proteins with 0.1 mol/1
NaOH (1.2 ml, 64 °C, 20 min). Afer-23-deoxycholic acid (10 nmol)
was then added. Bile acids were extracted by adsorption onto Bond
Elut® Cig cartridges and were eluted with methanolrwater
(10 + 90, by vol) (5 ml), methanolrwater (30 + 70, by vol) (5 ml)
and methanol ( 2 X 5 ml). The eluates were evaporated. The resi-
dues were dissolved in 2 ml 0.15 mol/1 phosphate buffer (pH 5.8)
and brought to pH 4.O. This mixture was then passed through a
Lipidex 1000® cartridge. Bile acids were eluted with water-acetic
acid (pH 4.0) ( 2 X 5 ml) and water-hydrochloric acid (pH 4.0)
( 2 X 5 ml). These acid eluates were kept for a further step. Bile
acids were eluted from the Lipidex 1000® cartridge with methanol-
:water (68 + 32, by vol) (10 ml) and methanol (10 ml). These Lip-
idex®-methanol-eluates were kept for a further step. The acid elu-
ates were run onto a new Bond Elut® cartridge, and bile acids were
eluted with methanohwater (10 + 90,by vol) (5 ml), methanol:-
water (30 + 70, by vol) (5 ml) and methanol (8 ml) (Bond Elut®-
methanol-eluates). The Lipidex®-methanol-eluates and Bond
Elut®-methanol-eluates were pooled and evaporated. 5a-Choles-
tane (10 nmol) was added. Bile acids were methylated with metha-
nolic-hydrochloric acid (2 ml) (25 °C, 8 h). The mixture was evap-
orated, trimethylsilylated with Tri-Sil® reagent (200 μΐ, 60 °C,
15 min) and evaporated. Finally, the bile acids were dissolved in
hexane (200 μΐ).
Chromatography
GC-MS analysis was performed on an HP 5890 series II gas chro-
matograph (Hewlett-Packard, Sunnyvale, CA, USA) equipped with
an HP-5 MS capillary column (30 m X 0.25 mm I. D., 0.25 urn
film thickness ref number 19091S-433) which was connected to an
HP 5971 A mass spectrometer. Helium was the carrier gas (flow
rate : 1.8 ml/min); the oven temperature was 50 °C for 2 minutes,
increased to 220 °C (20 °C/min), then 295 °C (2 °C/min), and was
295 °C for 10 min; the temperature was 250 °C, 280 °C and 180 °C
for the injection port, the transfer line and the ion-source, respec-
tively. The MS system was run in electron impact mode with 70
eV electron energy. The methylether-trimethylsilylesters of bile
acids in hexane (1 μΐ) were injected manually in splitless mode.
5a-Cholestane and the bile acids were identified by their R com-
pound values calculated with reference to «or-23-deoxy cholic acid
(tab. 1) and their mass spectrum data were taken from commercial
reference compounds and tables (15). C2?-bile acids, like trihydroxy-
cholestanoic acid (THCA), dihydroxycholestanoic acid, or varanic
acid (THCA-24-ol) and €29 dicarboxylic bile acid, were not avail-
able commercially although some standard C27-bile acids were syn-
thesized (16). The C2?-bile acids and €29 dicarboxylic bile acid
were identified by their R compound values (tab. 1) and their mass
spectrum data were compared to reference compound tables (15).
C24-bile acids were quantified by measuring the area under the
peak using the internal standard method with 5ct-cholestane and
C27-bile acids and €29 dicarboxylic bile acid with the standard
curve for cholic acid.
Analytical validation of the GC-MS method
Calibration curves were constructed using concentrations of 2, 4,
10, 20, 30 μπιοΐ/ΐ. The detection limit was determined as the con-
centration of bile acids at which the signal-to-noise ratio was s 3,
with a coefficient of variation less than 15% (n = 5). The precision
(correlation coefficients) and measured concentration (mean ±
standard deviation) were determined using stock serum with low
(n = 5), medium (n = 5), and high concentrations (n = 5) for in-
tra-day precision and on 5 subsequent days for inter-day precision.
Accuracy and recovery data were obtained with serum added with
working standards of bile acids (2, 4, 10, 20 and 30 μπιοΐ/ΐ)
(n = 5). Recovery studies were also performed by assaying human
cholestatic serum (n = 43) containing «or-23-deoxycholic acid
(10 nmol).
Total serum bile acid analysis
Total bile acids were measured using the 3a-hydroxysteroid dehy-
drogenase method (Enzabile®; Nycomed, Oslo, Norway).
Comparison of Enzabile®, GC-MS and
HPLC procedures
Samples from patients suffering from various cholestatic diseases
(n = 43), with or without ursodeoxycholic acid treatment, were an-
alysed. The data for total bile acids measured by Enzabile® and
calculated from GC-MS and HPLC by adding the specific bile
acids identified were compared as were the bile acids profiles ob-
tained with the GC-MS and HPLC methods. Statistical analysis
was performed with the Student's test and ρ < 0.05 was used as
the criterion of statistical significance.
Measurement of C24- and C2?-bile acids and
C29 dicarboxylic bile acid by GC-MS
Patients with generalized peroxisomal deficiencies, such as Zell-
weger syndrome (n = 5), neonatal adrenoleukodystrophy (n = 1)
and infantile Refsum disease (n = 2) and a single peroxisomal en-
zyme deficiency (n = 1) as bifunctional protein or thiolase activity
were analysed.
Tab. 1 Retention times of 5a-cholestane and bile acids (Rcompound
values) related to «or-23-deoxycholic acid and correlation coeffi-
cients of standard curves
Analyte Relative Correlation
retention coefficient
time of standard
curves
5a-Cholestane
nor-23-Deoxycholic acid
Lithocholic acid
Deoxycholic acid
Chenodeoxycholic acid
Cholic acid
Ursodeoxycholic acid
Trihydroxycholestanoic acid
Dihydroxycholestanoic acid
Varanic acid
C29-Dicarboxylic bile acid
0.800
1.000
1.041
1.093
1.111
1.117
1.152
1.298
1.298
1.414
1.778
0.997
0.997
0.997
0.997
0.997
0.996
Results
Validation of the GC-MS procedure
The detection limit was 0.4 |imol/l. The method was lin-
ear over the range 2—30 μπιοΙ/l.The correlation coeffi-
cients of standard curves were 0.997 and 0.996, respec-
tively (tab. 1). The intra-day precisions were
1.91-5.92%, 1.18-4.71%, 0.81-4.39% for the low,
medium and high concentrations, respectively and the
equivalent inter-day precisions were 2.16—7.45%,
3.57-9,52% and 2.14-4.44%. The overall values of re-
coveries of standard bile acids added to serum samples
were 82.6%-111.3% for 2 μιηοΐ/ΐ and were
99.5%-102.7% for 30 μιηοΐ/ΐ. Recovery of «or-23-de-
oxycholic acid was 96.2 ± 3.1% (n = 43).
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Tab. 2 Correlation coefficients and linear regression for compari- matography/ mass spectrometry (GC-MS) and the enzymatic
son of high performance liquid chroma
Analyte
Total €24 bile acids
Cholic acid
Chenodeoxycholic acid
Deoxycholic acid
Lithocholic acid
Ursodeoxycholic acid
itography (HPLC), gas chro- method (1
Compared
GC-MS/ HPLC
HPLC/ Enzabile®
GC-MS/ Enzabile®
GC-MS/ HPLC
GC-MS/ HPLC
GC-MS/ HPLC
GC-MS/ HPLC
GC-MS/ HPLC
Enzabile®)
n
43
22
22
43
41
28
21
22
r
0.990
0.986
0.998
0.993
0.980
0.916
0.593*
0.988
y
l.OOx + 8.58
0.79x + 4.45
0.87x + 6.18
0.98x - 0.66
1.03x+ 1.25
0.88x + 0.32
0.48x + 0.73
0.91x + 8.03
* p < 0.05
Comparison of HPLC and GC-MS
The correlation coefficients and linear regression for to-
tal and individual C24-bile acids are given in table 2.
GC-MS analysis of atypical bile acids
The following mean ratios were calculated for patients
with peroxisomal disorders:
C27-bile acids + C29 dicarboxylic bile acid(a)  — — - -  = 86%
total bile acids
trihydroxycholestanoic acid(b) — -  -  = 0.6 to 18
cholic acid
dihydroxycholestanoic acid
u — ι — ΪΓΡ — τ~chenodeoxychohc acid = °·39 to 5·43
(d)
trihydroxycholestanoic acid + C2g dicarboxylic bile acid
cholic acid
= 1.71 to 34.6*
* d > b in 78% of the patients
Accumulation of varanic acid was found in the serum of
a patient with the single peroxisomal enzyme deficiency.
Discussion
Extraction of serum bile acids should ensure the selec-
tive recovery of bile acids with polarities between those
of lithocholic acid and cholic acid and remove any com-
pounds likely to interfere with their spectral properties
in HPLC-UV or their structural data in GC-MS analyses.
Serum bile acids were usually extracted by liquid-solid
phase adsorptions as first described by Dyfverman &
Sj vall (17), and Setchell & Matsui (18). Although a
recent study has pointed out the superiority of triethyl-
amine sulphate for the safety against potential degrada-
tion of Bond Elut® cartridges by alkaline eluates, we
have not worried about this question (19). The recover-
ies of total bile acids and the overall analytical proper-
ties of the GC-MS method used were satisfactory. The
total bile acids concentrations obtained by the Enzabile®
procedure were well correlated with the values obtained
with the GC-MS and HPLC processes.The concentra-
tions of cholic acid, chenodeoxycholic acid and deoxy-
cholic acid measured by HPLC and by GC-MS were
well correlated, despite the bias introduced by HPLC not
measuring physiological unconjugated bile acids which
does not increase in cholestatic diseases (20) and sul-
phated bile acids were not measured by either methods.
These results indicate no detectable loss of bile acids
during the enzymatic or derivatization steps. Impurities
and matrix constituents with absorptivity at 200 nm af-
fected the identification of bile acids by HPLC, generat-
ing unidentified peaks even at trace level; the low molar
absorbances of bile acids in the UV spectrum were also
disturbing factors. Because of the limit of sensitivity for
HPLC, bile acids must be quantified by GC-MS when
the concentration is lower than 1 μηιοΐ/ΐ. Ursodeoxy-
cholic acid is currently used to treat cholestatic liver dis-
eases (21) and concentrations measured by GC-MS and
HPLC methods were well correlated. This optimized
sample preparation allowed us to measure, for the same
patient, the serum composition and conjugation profile
of bile acids with both the HPLC and GC-MS methods.
The system is also efficient in that similar reagents and
preparation procedures are used for both methods. The
biochemical screening for a peroxisomal disorder may
include a serum bile acids profile (22,23). Our ratio (d),
higher than ratio (b) (24) usually calculated, can be
added. We have developed a reliable, reproducible and
relatively easy GC-MS method, well correlated with
HPLC, for the determination of serum bile acid profiles.
FAB MS/MS was very efficient for a rapid identification
of bile acids without multi-step preparation of the sam-
ple, but isomers are not separated and this method is not
quantitative (10). A quantitative composition and conju-
gation profile of bile acids provides information on bile
acids metabolism, such as detoxifying pathways or per-
oxisomal defects that occur during liver diseases.
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